Literature DB >> 28275953

Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide.

David Bibi1, Hafiz Mawasi1, Alessio Nocentini2, Claudiu T Supuran2, Bogdan Wlodarczyk3, Richard H Finnell3, Meir Bialer4,5.   

Abstract

Epilepsy is one of the most common neurological diseases, with between 34 and 76 per 100,000 people developing epilepsy annually. Epilepsy therapy for the past 100+ years is based on the use of antiepileptic drugs (AEDs). Despite the availability of more than twenty old and new AEDs, approximately 30% of patients with epilepsy are not seizure-free with the existing medications. In addition, the clinical use of the existing AEDs is restricted by their side-effects, including the teratogenicity associated with valproic acid that restricts its use in women of child-bearing age. Thus, there is an unmet clinical need to develop new, effective AEDs. In the present study, a novel class of carbamates incorporating phenethyl or branched aliphatic chains with 6-9 carbons in their side-chain, and 4-benzenesulfonamide-carbamate moieties were synthesized and evaluated for their anticonvulsant activity, teratogenicity and carbonic anhydrase (CA) inhibition. Three of the ten newly synthesized carbamates showed anticonvulsant activity in the maximal-electroshock (MES) and 6 Hz tests in rodents. In mice, 3-methyl-2-propylpentyl(4-sulfamoylphenyl)carbamate(1), 3-methyl-pentan-2-yl-(4-sulfamoylphenyl)carbamate (9) and 3-methylpentyl, (4-sulfamoylphenyl)carbamate (10) had ED50 values of 136, 31 and 14 mg/kg (MES) and 74, 53, and 80 mg/kg (6 Hz), respectively. Compound (10) had rat-MES-ED50 = 13 mg/kg and ED50 of 59 mg/kg at the mouse-corneal-kindling test. These potent carbamates (1,9,10) induced neural tube defects only at doses markedly exceeding their anticonvuslnat-ED50 values. None of these compounds were potent inhibitors of CA IV, but inhibited CA isoforms I, II and VII. The anticonvulsant properties of these compounds and particularly compound 10 make them potential candidates for further evaluation and development as new AEDs.

Entities:  

Keywords:  4-Aminobenzensulfonamides; Carbonic anhydrase inhibition; New antiepileptic drugs; Teratogenicity; Valproic acid

Mesh:

Substances:

Year:  2017        PMID: 28275953     DOI: 10.1007/s11064-017-2216-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  39 in total

Review 1.  Development of new antiepileptic drugs: challenges, incentives, and recent advances.

Authors:  Emilio Perucca; Jacqueline French; Meir Bialer
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

2.  Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE).

Authors:  Robert S Fisher; Walter van Emde Boas; Warren Blume; Christian Elger; Pierre Genton; Phillip Lee; Jerome Engel
Journal:  Epilepsia       Date:  2005-04       Impact factor: 5.864

Review 3.  Chemical properties of antiepileptic drugs (AEDs).

Authors:  Meir Bialer
Journal:  Adv Drug Deliv Rev       Date:  2011-11-21       Impact factor: 15.470

4.  Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus.

Authors:  Piia Halmi; Seppo Parkkila; Jari Honkaniemi
Journal:  Neurochem Int       Date:  2005-11-04       Impact factor: 3.921

Review 5.  Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).

Authors:  Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Journal:  Epilepsia       Date:  2017-01-23       Impact factor: 5.864

6.  Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.

Authors:  Angela Casini; Jochen Antel; Francesco Abbate; Andrea Scozzafava; Samuel David; Harald Waldeck; Siegfried Schäfer; Claudiu T Supuran
Journal:  Bioorg Med Chem Lett       Date:  2003-03-10       Impact factor: 2.823

7.  Valproic acid-induced changes in gene expression during neurulation in a mouse model.

Authors:  B C Wlodarczyk; J C Craig; G D Bennett; J A Calvin; R H Finnell
Journal:  Teratology       Date:  1996-12

8.  Structure-activity relationships of unsaturated analogues of valproic acid.

Authors:  J Palaty; F S Abbott
Journal:  J Med Chem       Date:  1995-08-18       Impact factor: 7.446

9.  Characterization of the anticonvulsant profile of valpromide derivatives.

Authors:  Silvina M Tasso; Sung Ch Moon; Luis E Bruno-Blanch; Guillermina L Estiú
Journal:  Bioorg Med Chem       Date:  2004-07-15       Impact factor: 3.641

10.  Seizure control by decanoic acid through direct AMPA receptor inhibition.

Authors:  Pishan Chang; Katrin Augustin; Kim Boddum; Sophie Williams; Min Sun; John A Terschak; Jörg D Hardege; Philip E Chen; Matthew C Walker; Robin S B Williams
Journal:  Brain       Date:  2015-11-25       Impact factor: 13.501

View more
  2 in total

1.  Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2,4,6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor.

Authors:  Vincenzo Alterio; Davide Esposito; Simona Maria Monti; Claudiu T Supuran; Giuseppina De Simone
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

2.  Synthesis and Enantioselective Pharmacokinetic/Pharmacodynamic Analysis of New CNS-Active Sulfamoylphenyl Carbamate Derivatives.

Authors:  Reem Odi; David Bibi; Bella Shusterman; Natalia Erenburg; Chanan Shaul; Claudiu T Supuran; Alessio Nocentini; Meir Bialer
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.